▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : 640902470
▶ Storage : Airtight container, store at room temperature (1 to 30℃)
White elliptical tablet
Methylprednisolone 4mg
1. Initial dose may vary from 4mg to 48mg methylprednisolone a day depending on the symptoms of specific illnesses. While low doses are generally sufficient for cases less than severe, high initial doses may be required for special patients. The initial dose must be maintained or adjusted until a satisPlant reaction is yielded. If satisPlant clinical results are not yielded even after a sufficient period, cease administration and switch to another suitable therapy. Doses must be determined individually depending on the various illnesses being treated and the reactivity of the patient. After a suitable reaction appears, a suitable maintenance dose must be determined by reducing the initial dose at adequate intervals until the minimum dose able to maintain appropriate clinical reaction is reached. Sustained monitoring of doses is required. Cases wherein dose adjustments are necessary may include alleviation or exacerbation of illness, drug reactivity of individual patients, and exposure to environments applying stress not directly impacting the symptoms of the illness being treated. In the latter case, there may be a need to increase dose for such a period necessary to return the patient to a satisPlant state. When discontinuing the drug after prolonged therapy, gradual reduction of dose is preferable.
2. Multiple sclerosis
For treatment of acute exacerbation of multiple sclerosis, daily administration of 200mg prednisolone for 1 week followed by administration of 80mg prednisolone every other day for 1 month is effective (4mg methylprednisolone is equal to 5mg prednisolone).
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia, Nonsuppurative thyroiditis, Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis, Acute and subacute bursitis, Synovitis of osteoarthritis, Acute nonspecific tenosynovitis, Post-traumatic osteoarthritis, Psoriatic arthritis, Epicondylitis, Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, Systemic dermatomyositis (polymyositis), Acute rheumatic carditis
4. Dermatologic Diseases, Bullous dermatitis herpetiformis, Severe erythema multiforme (Stevens-Johnson syndrome), Severe seborrheic dermatitis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis, Drug hypersensitivity reactions, Serum sickness, Contact dermatitis, Bronchial asthma, Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers, Herpes zoster ophthalmicus, Anterior segment inflammation, Diffuse posterior uveitis and choroiditis, Sympathetic ophthalmia, Keratitis, Optic neuritis, Allergic conjunctivitis, Chorioretinitis, Iritis and iridocyclitis
7. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: Ulcerative colitis, Regional enteritis
8. Respiratory Diseases
Symptomatic sarcoidosis, Berylliosis, Loeffler's syndrome not manageable by other means, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, Aspiration pneumonitis
9. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), Congenital (erythroid) hypoplastic anemia
10. Neoplastic Diseases
For palliative management of: Leukemias and lymphomas in adults, Acute leukemia of childhood,
11. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
12. Nervous System
Acute exacerbations of multiple sclerosisWhite elliptical tablet
Methylprednisolone 4mg
1. Initial dose may vary from 4mg to 48mg methylprednisolone a day depending on the symptoms of specific illnesses. While low doses are generally sufficient for cases less than severe, high initial doses may be required for special patients. The initial dose must be maintained or adjusted until a satisPlant reaction is yielded. If satisPlant clinical results are not yielded even after a sufficient period, cease administration and switch to another suitable therapy. Doses must be determined individually depending on the various illnesses being treated and the reactivity of the patient. After a suitable reaction appears, a suitable maintenance dose must be determined by reducing the initial dose at adequate intervals until the minimum dose able to maintain appropriate clinical reaction is reached. Sustained monitoring of doses is required. Cases wherein dose adjustments are necessary may include alleviation or exacerbation of illness, drug reactivity of individual patients, and exposure to environments applying stress not directly impacting the symptoms of the illness being treated. In the latter case, there may be a need to increase dose for such a period necessary to return the patient to a satisPlant state. When discontinuing the drug after prolonged therapy, gradual reduction of dose is preferable.
2. Multiple sclerosis
For treatment of acute exacerbation of multiple sclerosis, daily administration of 200mg prednisolone for 1 week followed by administration of 80mg prednisolone every other day for 1 month is effective (4mg methylprednisolone is equal to 5mg prednisolone).
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia, Nonsuppurative thyroiditis, Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis, Acute and subacute bursitis, Synovitis of osteoarthritis, Acute nonspecific tenosynovitis, Post-traumatic osteoarthritis, Psoriatic arthritis, Epicondylitis, Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, Systemic dermatomyositis (polymyositis), Acute rheumatic carditis
4. Dermatologic Diseases, Bullous dermatitis herpetiformis, Severe erythema multiforme (Stevens-Johnson syndrome), Severe seborrheic dermatitis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis, Drug hypersensitivity reactions, Serum sickness, Contact dermatitis, Bronchial asthma, Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers, Herpes zoster ophthalmicus, Anterior segment inflammation, Diffuse posterior uveitis and choroiditis, Sympathetic ophthalmia, Keratitis, Optic neuritis, Allergic conjunctivitis, Chorioretinitis, Iritis and iridocyclitis
7. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: Ulcerative colitis, Regional enteritis
8. Respiratory Diseases
Symptomatic sarcoidosis, Berylliosis, Loeffler's syndrome not manageable by other means, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, Aspiration pneumonitis
9. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), Congenital (erythroid) hypoplastic anemia
10. Neoplastic Diseases
For palliative management of: Leukemias and lymphomas in adults, Acute leukemia of childhood,
11. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
12. Nervous System
Acute exacerbations of multiple sclerosis
